Skip to main content
. 2019 Jun 5;134(6):525–533. doi: 10.1182/blood.2018893545

Figure 3.

Figure 3.

Maximum TSS response on study. Nine patients treated with idasanutlin attained at least a 50% reduction in TSS. The cycle in which the best percentage reduction was first noted is shown in association with each patient response. NE, not evaluable; NR, no response.